Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 09:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics,...
January 29, 2026 09:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in...
January 05, 2026 09:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review...
February 20, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 18, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
November 25, 2024 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
November 14, 2024 16:15 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 06, 2024 07:30 ET | Source: Plus Therapeutics Inc.; Spectron RX

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
November 05, 2024 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
October 29, 2024 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas